Vol 70, No 6 (2019)
Original paper
Published online: 2019-09-30

open access

Page views 2049
Article views/downloads 1011
Get Citation

Connect on Social Media

Connect on Social Media

Assessment of selected adipocytokines in obese women with postmenopausal osteoporosis

Joanna Głogowska-Szeląg1, Beata Kos-Kudła1, Bogdan Marek1, Mariusz Nowak1, Lucyna Siemińska1
Pubmed: 31566247
Endokrynol Pol 2019;70(6):478-483.


Introduction: Osteoporosis and obesity are considered civilisation diseases. Menopause is a time of increased bone resorption and increased mass of adipose tissue. Adipocytokines secreted by the adipose tissue are believed to be a potential factor in the pathogenesis of osteoporosis.

Material and methods: The aim of this research was to assess leptin, adiponectin, and resistin secretion in obese postmenopausal women with osteoporosis and determine whether obesity might be a factor mitigating the risk of osteoporosis. The study involved 80 postmenopausal women with osteoporosis divided into groups: I with BMI of 30.0 34.9, obese; and II with BMI of 18–24.9, normoweight. Leptin, adiponectin and resistin concentrations were assessed, and bone mineral density (BMD) was measured in the L1-L4 section of the spine using the DXA densitometric method.

Results: The results of the comparison of the two groups indicate a statistically significant dependence in groups regarding leptin secretion; the group of obese women demonstrated significantly higher concentrations. No differences between the groups were demonstrated for adiponectin or resistin secretion.

Conclusions: Higher leptin concentration and a positive correlation with BMI was confirmed in obese postmenopausal women with osteoporosis. It was also demonstrated that BMD increases with growing BMI. No effect of obesity on the secretion of adiponectin or resistin in women with postmenopausal osteoporosis was found. From among the investigated adipocytokines, only leptin can be considered a bone tissue protective factor in postmenopausal women. 

Article available in PDF format

View PDF Download PDF file


  1. Compston J, Cooper A, Cooper C, et al. National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62(2): 105–108.
  2. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis — its clinical features. J Am Med Assoc. 1941; 116: 2465–2474.
  3. Zeng J, Li K, Gong Y, et al. Association of pro-inflammatory cytokines with QCT-measured bone mineral density and its gender difference in a Chinese population - a pilot study. Endokrynol Pol. 2019; 70(3): 248–254.
  4. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000; 11(8): 669–674.
  5. Oursler MJ, Landers JP, Riggs BL, et al. Oestrogen effects on osteoblasts and osteoclasts. Ann Med. 1993; 25(4): 361–371.
  6. Ravn P, Cizza G, Bjarnason NH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999; 14(9): 1622–1627.
  7. Liu Y, Song CY, Wu SS, et al. Novel adipokines and bone metabolism. Int J Endocrinol. 2013; 2013: 895045.
  8. Reid IR. Fat and bone. Arch Biochem Biophys. 2010; 503(1): 20–27.
  9. Albala C, Yauez M, Deroto E, et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996; 20(11): 1027–1032.
  10. Morcov C, Vulpoi C, Branisteanu D. Correlation between adiponectin, leptin, insulin-like growth factor-1 and bone mineral density in pre and post-menopausal women. Rev Med Chir Soc Med Nat Iasi. 2012; 116(3): 785–789.
  11. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013; 18: 12.
  12. Biver E, Salliot C, Combescure C, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96(9): 2703–2713.
  13. Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr. 2006; 83(1): 146–154.
  14. Siemińska L, Cichoń-Lenart A, Kajdaniuk D, et al. Hormony płciowe i adipocytokiny u kobiet po menopauzie. Pol Merk Lek. 2006; XX(120): 727–729.
  15. Cornish J, Callon KE, Bava U, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002; 175(2): 405–415.
  16. Ben-Eliezer M, Phillip M, Gat-Yablonski G. Leptin regulates chondrogenic differentiation in ATDC5 cell-line through JAK/STAT and MAPK pathways. Endocrine. 2007; 32(2): 235–244.
  17. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999; 140(4): 1630–1638.
  18. Leibel RL. The role of leptin in the control of body weight. Nutr Rev. 2002; 60(10 Pt 2): S15–S9; discussion S68.
  19. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002; 17(2): 200–209.
  20. Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149(4): 331–335.
  21. Horakova D, Stepanek L, Nagelova R, et al. Total and high-molecular-weight adiponectin levels and prediction of insulin resistance. Endokrynol Pol. 2018; 69(4): 375–380.
  22. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006; 21(10): 1648–1656.
  23. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004; 35(4): 842–849.
  24. Lee WY, Rhee EJ, Oh KiW, et al. Identification of adiponectin and its receptors in human osteoblast-like cells and association of T45G polymorphism in exon 2 of adiponectin gene with lumbar spine bone mineral density in Korean women. Clin Endocrinol (Oxf). 2006; 65(5): 631–637.
  25. Gomez R, Lago F, Gomez-Reino J, et al. Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. J Mol Endocrinol. 2009; 43(1): 11–18.
  26. Douchi T, Yamamoto S, Oki T, et al. Difference in the effect of adiposity on bone density between pre- and postmenopausal women. Maturitas. 2000; 34(3): 261–266.
  27. Tenta R, Kontogianni MD, Yiannakouris N. Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J Endocrinol Invest. 2012; 35(3): 306–311.
  28. Silva HG, Mendonça LMC, Conceição FL, et al. Influence of obesity on bone density in postmenopausal women. Arq Bras Endocrinol Metabol. 2007; 51(6): 943–949.
  29. Reid IR. Obesity and osteoporosis. Ann Endocrinol. 2006; 67: 125–129.
  30. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2(1): 35–43.
  31. Rosen CJ. Osteoporoza. Zasady rozpoznawania i leczenia. Springer PWN, Warszawa 1998: 16–22.
  32. Blain H, Vuillemin A, Guillemin F, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2002; 87(3): 1030–1035.
  33. Lecke SB, Morsch DM, Spritzer PM. Leptin and adiponectin in the female life course. Braz J Med Biol Res. 2011; 44(5): 381–387.
  34. Ostlund RE, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab. 1996; 81(11): 3909–3913.
  35. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005; 174(9): 5789–5795.
  36. Sodi R, Hazell MJ, Durham BH, et al. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism. Clin Biochem. 2009; 42(13–14): 1375–1380.
  37. Zoico E, Zamboni M, Bosello O. The consequences of aging on endocrine function of adipose tissue. Obes Metab. 2008; 4(1): 64–75.
  38. Kontogianni MD, Dafni UG, Routsias JG, et al. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res. 2004; 19(4): 546–551.
  39. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46(4): 459–469.
  40. Jürimäe J, Jürimäe T. Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int. 2007; 18(9): 1253–1259.
  41. Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf). 2002; 56(6): 703–711.
  42. Tenta R, Kontogianni MD, Yiannakouris N. Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. J Endocrinol Invest. 2012; 35(3): 306–311.
  43. Laughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (Lond). 2007; 31(3): 457–465.
  44. Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care. 2003; 26(8): 2383–2388.
  45. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–312.
  46. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab. 2004; 6(3): 163–170.